Breast cancer breakthrough as new test could revolutionise treatment
New breast cancer test predicts if disease could return
- A new test has been developed to predict whether breast cancer is likely to return just two weeks after treatment begins.
- Experts suggest this innovation could spare thousands of breast cancer patients from receiving unnecessary treatment.
- The test targets oestrogen receptor-positive, human epidermal growth factor receptor 2 positive breast cancer, a type accounting for around 200,000 global cases annually.
- Developed by scientists at The Institute for Cancer Research, London, the test identifies the 6 per cent of patients at highest risk of relapse.
- The findings aim to facilitate more precise and personalised treatment plans, guiding doctors on which patients need more intensive therapy.